Business context and reporting period
Soligenix, Inc. is a clinical-stage biopharmaceutical company reporting for the fiscal year ended December 31, 2013. Its two segments are BioTherapeutics and Vaccines/BioDefense. It had no significant product sales; reported revenue was principally reimbursement under government grants and contracts.
Key programs included SGX942 for oral mucositis, oral BDP candidates for gastrointestinal inflammatory conditions, and biodefense programs including OrbeShield, RiVax, VeloThrax, ThermoVax and melioidosis candidates SGX943/SGX101.
Financial and operating performance
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | $3.224 million | $3.145 million |
| Gross profit | $680,000; approximately 21.1% gross margin | $552,000; approximately 17.5% gross margin |
| Research and development expense | $5.071 million | $2.609 million |
| General and administrative expense | $2.765 million | $2.633 million |
| Operating loss | $7.157 million | $4.691 million |
| Net loss | $10.059 million; $0.65 per share | $4.163 million; $0.37 per share |
| Cash used in operating activities | $4.457 million | $2.636 million |
| Cash and cash equivalents at year-end | $5.856 million | $3.356 million |
At December 31, 2013, total assets were $8.265 million and current liabilities were $10.035 million, including an $8.281 million warrant liability. Management’s stated working capital of $5.855 million excludes that non-cash warrant liability; including it, current assets less current liabilities were approximately negative $2.426 million. The filing reports no interest-bearing debt balance. Stockholders’ equity was negative $1.770 million.
The company’s accumulated deficit was $132.339 million. Its June 2013 offering, Lincoln Park equity facility and exercises of options and warrants provided financing; year-end common shares outstanding rose to 19.626 million from 11.169 million.
Material changes versus the prior year
- Net loss increased by $5.896 million, or 142%, while operating loss increased by $2.466 million.
- R&D expense rose 94%, reflecting the SGX942 Phase 2 trial, preparation for SGX203 clinical development, and a $1.5 million non-cash stock issuance to Intrexon recognized as R&D expense.
- A $3.655 million non-cash fair-value charge on offering-related warrant liabilities substantially increased 2013 net loss. The liability was $8.281 million at year-end.
- Revenue rose modestly, mainly as OrbeShield government contracts began in the fourth quarter. Gross profit increased by $128,000, supported by contract overhead and management-fee reimbursement.
- Operating cash use increased by $1.821 million, principally due to clinical development spending, additional headcount and timing of New Jersey tax-credit proceeds.
Guidance, outlook, risks and unusual items
Management expected cash, grant and contract proceeds, potential Lincoln Park equity-facility proceeds and New Jersey NOL-sale proceeds to support at least twelve months of operations. It forecast approximately $10.8 million of R&D spending over the next twelve months, with about $6.8 million expected to be reimbursed under existing government contracts and grants. Management also cited up to $33.2 million in active grant and contract funding; some contract options require government exercise, and funding is program-restricted.
- In September 2013, BARDA and NIAID awarded OrbeShield development contracts with combined potential funding of up to $32.7 million, subject to options and contract terms.
- SGX942 Phase 2 had begun; data were expected in the second half of 2014. SGX203 Phase 2/3 and SGX201 Phase 2 were planned for the second half of 2014, with data expected in the second half of 2015. These were forward-looking plans, not assured milestones.
- OrbeShield had FDA IND clearance and promising canine-model findings, but remained preclinical. RiVax Phase 1B was complete, with a Phase 2 trial planned for the first half of 2015; VeloThrax remained preclinical.
- Important risks include clinical and regulatory failure, dependence on government funding and procurement, limited cash and potential need for further financing, dilution, reliance on external manufacturers and licensors, and competition. The company had not generated significant product sales and expected continued operating losses.
- A prior confirmatory Phase 3 trial of orBec for GI GVHD was stopped in 2011 after interim results indicated a low likelihood of meeting its efficacy endpoint. The company terminated development for acute GI GVHD; success in other BDP indications remained uncertain.
- New Jersey NOL sales generated a $750,356 tax benefit in 2013; continuation and value of the program were uncertain. The company carried a full valuation allowance against deferred tax assets, and noted potential Section 382 limits on NOL use.
Most important facts for investors to verify
- Whether the disclosed clinical timelines were met and whether trial results support further development and regulatory approval.
- How much of the stated government funding is committed base-period funding versus contingent options, and whether reimbursement keeps pace with program spending.
- Current cash runway and financing needs, particularly given operating cash use, negative equity and dependence on equity financing.
- The terms, valuation effects and potential dilution from the warrant liability, outstanding warrants and options, and Lincoln Park equity facility.
- Whether the New Jersey NOL-sale program continues and how much of the company’s tax attributes can ultimately be used.